1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Approvals

Minute Insight: Senseonics Eversense E3 CGM Receives CE Mark, Launch Planned For Q3

 
• By Marion Webb

Sensonics received the CE mark for its next-generation E3 CGM with plans to launch in the third quarter. It will be facing stiff competition from CGM makers Dexcom and Abbott in the European market.   

Minute Insight
• Source: Informa/Alamy

After making its debut in the US, Senseonics Holdings, Inc.’s next-generation, six-month Eversense E3 continuous glucose monitoring (CGM) received a CE mark, the company announced on 16 June. Senseonics plans to launch its Eversense E3 GCM in certain European countries starting in the third quarter.

Both, the implantable Eversense E3 CGM and Eversense XL CGM (available in Europe since 2017), have a 180-day sensor, but...

Welcome to Medtech Insight

Create an account to read this article

Already a subscriber?

More from Approvals

Study: FDA’s Breakthrough Path Speeds Access, But Raises Safety Questions

 
• By Elizabeth Orr

Research recently published in JAMA Internal Medicine found that the FDA met its review timeline goals for the majority of breakthrough devices – but also revealed some apparent shortcomings in safety data supporting the submissions.

FDA Commissioner’s Voucher Program Should Include Devices, Transplant Technology Firm Says

 
• By Elizabeth Orr

The FDA's new Commissioner’s National Priority Voucher program aims to expedite drug approvals significantly. Device firms like XVIVO advocate for a similar initiative for devices, emphasizing the potential for faster reviews and improved patient access to lifesaving technologies.

FDA Greenlights Expanded Use Of Boston Scientific’s Pulse Field Ablation System

 
• By Brian Bossetta

A recent approval from the US FDA allowing Boston Scientific to broaden its labeling for its pulse field ablation system means more patients with one type of AFib will have access to a promising new treatment.

South Korean Health Ministry Sees Benefits Of Pre-Regulatory Review

 
• By Jung Won Shin

A system of pre-regulatory review consultations for innovative drugs and devices in South Korea has contributed to the accelerated development of such products.

More from Policy & Regulation

HealthAI: ‘Established Regulations Already Exist For Regulating AI In Healthcare Safely’

 
• By Natasha Barrow

Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.

EUDAMED Notice Anticipated By September As Commission Optimizes Operations

 
• By Amanda Maxwell

The last steps are taking place leading to the launch of the EU’s medical device database, EUDAMED.

From Imitation To Action: Johns Hopkins Robot Autonomously Performs Key Step In Gallbladder Surgery

 
• By Marion Webb

Researchers at Johns Hopkins have used a robotic system to autonomously perform a key part of gallbladder surgery without a surgeon's hand. Lead author Axel Krieger says it could take five to 10 years before an autonomous robotic system will reach human trials and expects regulatory hurdles.